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ABSTRACT
INTRODUCTION: Group B streptococci (GBS) can cause pre­
term delivery for women and sepsis and meningitis in in­
fants younger than 90 days of age. The present retrospect­
ive cohort study determines the trend over time in the rates 
of GBS and in demographic risk factors for GBS among preg­
nant women delivering at Rigshospitalet (RH). 
MATERIAL AND METHODS: In the period from 2002 to 2010, 
a total of 33,616 women gave birth at the RH. Our cohort 
was defined as 16,587 (49%) women examined by 24,724 
cultures. All microbiological requisitions from the Depart­
ment of Obstetrics at RH were extracted from the Clinical 
Microbiology Database. Maternal data were obtained from 
a local database at the RH.
RESULTS: In our cohort, a total of 638 (3.8%) women were 
diagnosed with GBS, 517 (81%) from urine, 92 (14%) from 
vaginal swabs and 29 (5%) from both. The overall rate of 
women colonised with GBS rose from 3.3% in 2002 to 5.1% 
in 2010 (p < 0.0001). A total of 48 infants had early­onset 
group B streptococcus (EOGBS), 1.4 per 1,000 neonates in 
the general population and 7.8 per 1,000 among women 
with GBS (p < 0.0001). 
CONCLUSION: We found a low GBS colonisation rate in our 
pregnant cohort, but the rate followed an increasing trend 
over the study period. GBS during pregnancy was associ­
ated with a low birth weight and preterm delivery. More re­
search on preventive measures is needed, but updated 
guidelines, screening and intrapartum antibiotic prophylaxis 
continue to be the cornerstones of EOGBS disease preven­
tion. 
FUNDING: not relevant.
TRIAL REGISTRATION: not relevant.
Group B streptococci (GBS) can cause preterm delivery 
for women and sepsis and meningitis in infants younger 
than 90 days of age. Maternal colonisation with GBS in 
the genitourinary tract is the primary risk factor [1]. Col­
onisation is generally asymptomatic and only occasion­
ally associated with urinary tract infection [2]. Early­ 
onset GBS (EOGBS) < 1 week of age is the leading cause 
of serious neonatal infections in the UK and the US [2, 
3]. The incidence of EOGBS disease has declined over 
the past 15 years, from 1.7 cases per 1,000 live births in 
the early 1990s to 0.34­0.37 cases per 1,000 live births 
in recent years [4]. In the 1970s, the fatality rate among 
babies with EOGBS was approximately 50% in the US, 
but the rate has declined to 4­6% in recent years, pri­
marily owing to advances in neonatal care [1, 3, 5].
Despite improvements in medical care, GBS remains 
an important cause of perinatal morbidity and mortality. 
The prevalence of diseases caused by invasive beta­
haemolytic streptococci is rising in Denmark [6]. The re­
ported colonisation rate among Danish women in ob­
stetrical cohorts fluctuates from 8% to 36%, despite the 
fact that the cohorts were remarkably homogeneous [7, 
8]. In a recent review, the GBS vaginal colonisation rates 
in Europe ranged from 6.5% to 36%, similar to the US 
where 10­30% of pregnant women are colonised [5, 9]. 
There are competing strategies for the prevention of 
EOGBS disease. In the US, universal culture­based 
screening has yielded a substantial decline in disease in­
cidence since it was recommended in 2002 [10]. At 
Rigshospitalet (RH), intrapartum antibiotic prophylaxis 
(IAP) has been administered based on a risk­factor­
based approach since 2004. IAP is administered to  
women with preterm delivery < 37 gestational weeks, 
intrapartum temperature > 38° C, amniotic membrane 
rupture ≥ 18 hours, GBS bacteriuria during any trimester 
of the current pregnancy, or a previous infant with inva­
sive GBS disease [11]. 
This study describes the incidence of mothers with 
a positive GBS culture during pregnancy who gave birth 
at RH, and it describes the association between the inci­
dence and neonatal GBS morbidity and mortality in the 
2002­2010 period. 
MATERIAL AND METHODS
Definition of the cohort
We conducted a retrospective cohort study on all deliv­
eries at the RH from 2002 to 2010. The cohort included 
33,616 women. Maternal data were obtained from a  
local RH database by using the Danish Personal Identifi­
cation number (CPR). The obstetrical and neonatal data 
were obtained from a local obstetrical database (OD) 
covering RH and Hvidovre Hospital. We extracted all mi­
crobiological requisitions from the Clinical Microbiology 
Database (MADS) at the RH. If a woman had a minimum 
of one positive bacterial sample with GBS, she was de­
fined as GBS­positive. The following data were extracted 
for each woman: date and gestational age at birth, birth 
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weight, pH in the umbilical cord, Apgar score, mode of 
delivery, maternal age at delivery, parity, maternal body 
mass index (BMI) and smoking habits. The study popula­
tion with in­ and exclusions is described in Figure 1.
To identify the neonates with a positive bacterial 
culture for GBS, we used MADS at the RH. We defined 
the search to include all neonates aged 0­90 days with at 
least one positive GBS bacterial culture (blood, cerebro­
spinal fluid and swabs from the trachea) and admission 
to the neonatal ward due to septicaemia. From 2002 to 
2010, we identified 48 neonates matching these criteria. 
We identified their mothers and data regarding delivery 
from the OD. 
Microbiological cultures
The samples were collected according to departmental 
guidelines. Indications for urine samples were prema­
ture contractions, preterm pre­labour rupture of mem­
branes (PPROM), symptoms of urinary tract infections 
and former preterm delivery, etc. Indications for vaginal 
swabs were PPROM or possible infections.
The urine samples were collected as clean catch 
urine. If the transportation time to the laboratory ex­
ceeded two hours, the samples were stored in refrigera­
tors. 
In brief, all urine samples were handled as follows 
throughout the period: microscopy was performed on all 
urine samples and 100 µl were cultured on 5% Danish 
blood agar (DBA). In case of bacteria visualised by mi­
croscopy, we added a “blue plate” (modified Conradi 
Drigalski’s medium) selective for Gram­negative rods, a 
tellur plate (State Serum Institute, Copenhagen, 
Denmark), a blood agar resistance plate and a chromID 
CPS plate (BioMerieux) specific for GBS. Bacteria with 
different susceptibility patterns and different colony 
morphologies were chosen and identified according to 
internal laboratory manuals. 
The vaginal swabs were collected by swabbing the 
lower vagina and were stored in transportation media 
and handled as mentioned above.
Vaginal swabs were cultured on 5% DBA, a “blue 
plate”, a Chrom agar plate for Candida species, a 
Gonococci plate and a Gardnerella plate. All cultures 
were incubated for two days. The DBA was incubated in 
CO2 to promote growth of GBS. 
Statistics
The Pearson χ2­test was applied to compare frequen­
cies. Differences in frequencies were summarised by 
odds ratios (OR). Confidence intervals (CI) for propor­
tions were calculated based on the clog­log transform. 
Univariable logistic regression analyses were performed 
to examine the associations between calendar year and 
risk of positive GBS bacterial culture and adverse neona­
tal outcomes. 
Ethics approval
The study was approved by the Danish National Data 
Protection Agency. Reference number: 41­0569. (Date: 1 
March 2011). 
Trial registration: not relevant.
FIGURE 1
Patient flow chart.
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FIGURE 2
Group B streptococci colonisation rate, incidence of women with Group 
B streptococci during pregnancy and preterm delivery, Obstetrical requi­
sitions and incidence of early­onset Group B streptococci per 1,000 neo­
nates among women giving birth at Rigshospitalet from 2002 to 2010.
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RESULTS
Colonisation and infections with group B streptococci
From 2002 to 2010, a total of 33,616 women delivered 
at the RH. Of these, 16,587 (49%) were examined with a 
vaginal swab or urine culture or both. Overall, 3,270 of 
the 16,587 women (19.7%) were culture­positive for any 
bacteria. 
We identified 5,518 positive cultures from 3,270 
women and 3,369 pregnancies. The main sample cate­
gories of the positive cultures were 3,803 urine tests 
(67%) and 1,242 vaginal swabs (22%). The proportion of 
pregnancies with at least one examination for GBS 
ranged between 37% and 60% of the annual birth cohort 
during the study period (Table 1).
We identified 638 women with GBS (510 urine sam­
ples, 85 vaginal swabs, 29 with a culture­positive urine 
and vaginal swab, 14 from other categories). The overall 
rate of women colonised by GBS in our cohort was 3.9% 
(638/16,587; 95% CI: 3.6­4.1%). The GBS colonisation 
rate in our cohort varied from 2.8% to 5.1% (Figure 2 
and Table 1). Our data demonstrate a significant in­
crease in GBS­positive samples in our cohort from 3.3% 
(53/1,598) in 2002 to 5.1% in 2010 (102/1,988) (OR = 
1.07; 95% CI: 1.04­1.11; p < 0.0001 per year). The overall 
rate of GBS­positive samples increased significantly from 
13% (53/418) in 2002 to 29% (102/357) in 2010 (OR = 
1.13; 95% CI: 1.09­1.17; p < 0.0001 per year). We found 
a similar, significant increase in both GBS­positive vagi­
nal swabs (OR = 1.21; 95% CI: 1.11­1.31; p < 0.0001 per 
year) and GBS in urine (OR = 1.12; 95% CI: 1.08­1.16; p < 
0.0001 per year).  
In the youngest and oldest maternal age groups, we 
found a tendency towards an increased risk of GBS. 
Furthermore, we found an increased risk in multiparity 
(Table 2). 
Early-onset group B streptococci
We identified 48 neonates with EOGBS. The incidence of 
EOGBS was five in 638 (0.7%) infants born by mothers 
with a positive GBS culture compared with 39 (0.2%) in 
30,247 in the women with no diagnosed infection during 
pregnancy, and four infants (0.1%) born by mothers with 
culture­positive samples, but with other bacteria than 
GBS. Women with a positive culture for GBS during preg­
nancy had an increased risk of giving birth to an infant 
with GBS septicemia compared with women with a  
negative GBS culture (OR = 6.05; 95% CI: 2.39­15.32). 
We observed no difference in the risk of delivery of a 
child with GBS septicemia between mothers with a  
negative GBS culture sample and mothers with a posi­
tive culture with bacteria other than GBS. There were no 
neonatal deaths due to GBS among the 48 neonates. Of 
the neonates with GBS culture­positive mothers, three 
out of five received intrapartum antibiotic prophylaxis 
(IAP) in relation to a caesarean section. In total, 21 
mothers to the 48 neonates with EOGBS received IAP. 
Duration of labour, prelabour rupture of membranes/
premature prelabour rupture of membranes and  
obstetrical outcomes
We examined the duration from rupture of membranes 
(ROM) to delivery among the 48 neonates. This informa­
tion was available for 40 cases. Our data showed that 
only 5% (two out of 40 neonates) (95% CI: 1­15%) had a 
prolonged ROM (> 18 hours), and none exceeded 22 
hours. 
There was no trend in either pre­labour ROM 
(PROM) or premature pre­labour ROM (PPROM) over 
time in our cohort. But in the women with GBS, we 
found 4.2% (27/638; 95% CI: 2.9­6.0%) with PPROM 
compared with 2.9% (940/32,978; 95% CI: 2.7­3.0%) in 
TABLE 1
Examination rate, group B streptococci colonisation rate and incidence of early­onset group B streptococci from 2002 to 2010.
2002 2003 2004 2005 2006 2007 2008 2009 2010 Total
Deliveries in Denmarka, n 62,315 62,812 62,874 62,545 63,201 62,535 63,327 61,131 61,445 562,185
Deliveries at RH, n 3,074 3,303 3,220 3,316 3,729 3,954 3,783 3,864 5,373 33,616
Examination rate, % 52 44 49 56 53 50 51 60 37 49
Women with a positive GBS culture during pregnancy, n 53 40 55 58 63 78 89 100 102 638
GBS colonisation rate, % 3.3 2.8 3.5 3.2 3.2 4.0 4.6 4.3 5.1 3.9
National incidence of preterm deliveriesa, % 6.2 6.3 6.3 6.2 6.2 6.4 6.0 5.8 5.8  6.1
Incidence of preterm deliveries RH, % 10.9 10.7 11.0 11.3 10.7 10.4 10.8 11.5 8.1 10.5
Women with GBS during pregnancy and preterm delivery, n 11 10 15 11 15 23 16 18 25 144
Incidence of women with preterm delivery and GBS during pregnancy, % 3.3 2.9 4.2 2.9 3.8 5.6 3.9 4.0 5.7 4.1
Neonates with EOGBS, n 7 6 6 4 6 6 5 1 7 48
Incidence of EOGBS per 1,000 neonates, n 2.3 1.8 1.9 1.2 1.6 1.5 1.3 0.3 1.3 1.4
EOGBS = early­onset group B streptococci < 1 week of age; GBS = group B streptococci; RH = Rigshospitalet. 
a) Source: Danish Health and Medicines Authority.
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the background population of 32,978 deliveries (OR = 
1.51; 95% CI: 1.02­2.23; p = 0.039). 
Colonisation with GBS during pregnancy increased 
the risk of preterm delivery < 37 weeks (OR = 2.06; 95% 
CI: 1.70­2.48), low birth weight < 2,000 g (OR = 2.46; 
95% CI: 1.95­3.11) and of instrumental vaginal, elective 
caesarean section and emergency caesarean section (OR 
= 3.25; 95% CI: 2.76­3.83) (Table 2). The incidence of 
GBS among the women with preterm delivery increased 
from 3.3% (95% CI: 1.7­5.6%) in 2002 to 5.7% (95% CI: 
3.8­8.2%) in 2010 (Table 1).  In the trend analysis, we 
found that the risk of a GBS­positive culture tended to 
increase over time (OR = 1.07; 95% CI: 1.00­1.14; p = 
0.048).
DISCUSSION 
We found a significant increase in the number of GBS­
positive samples in our cohort over time, particularly 
among the young and elderly women and the multipar­
ous. We found an increased risk of preterm delivery 
among women colonised with GBS during pregnancy 
and, furthermore, a six­fold increased risk of delivery of 
a child with EOGBS in the perinatal period. The overall 
incidence of EOGBS was 1.4 cases per 1,000 live births, 
which is substantially higher than in other countries [12]. 
The national incidence of EOGBS was 0.6 cases per 1,000 
live births in 1995, but 0.2 cases per 1,000 live births in 
2002 [13]. The RH is a referral centre for preterm deliv­
eries; and selection bias may thus explain the higher EO­
GBS rate at the RH. Over time we found a decrease in 
the incidence of EOGBS from 2.27 cases per 1,000 live 
births in 2002 to 1.30 cases per 1,000 live births in 2010. 
This decrease could be caused by the introduction of IAP 
from 2004 [11] and further by a hospital fusion in 2009, 
which increased the proportion of low risk births at our 
unit. There are conflicting reports about GBS as a risk 
factor for preterm delivery or preterm rupture of mem­
branes [14­17] The increased risk of preterm birth in 
mothers with a positive GBS culture in our study could 
be due to more frequent testing of women with preterm 
or imminent preterm birth. 
Our data showed a rising trend in the prevalence of 
GBS­positive samples in women tested at the RH and an 
increase in the incidence of GBS in mothers with pre­
term deliveries. This was not followed by an increase in 
associated complications such as preterm delivery and 
EOGBS. Interpretation of the results should take into ac­
count that the examination rate varied from 37% to 60% 
during the study period and that there were no strict cri­
teria for performing the tests. Thus, we cannot docu­
ment a rising prevalence of GBS, but our results raise a 
suspicion that warrants further consideration. The colo­
nisation rate was low compared with earlier Danish 
studies, which could be due to the fact that our cultures 
were performed on indications and not as a general 
screening. By screening all pregnant women with vaginal 
swabs we would be able to find the asymptomatic, colo­
nised women and hence would observe a higher coloni­
sation rate [7, 13, 18]. 
TABLE 2
Demographic data, risk factors and obstetrical outcomes comparing our group B streptococci culture­
positive cohort of 638 women and all other deliveries from 2002 to 2010.
Demographic data
GBS-positive,  
n (%)
All other  
deliveries, n (%) OR (95% CI) p-valuea
Risk factors
Maternal age, yrs 0.0240
15­19     7 (4.1)       163 (95.9) 2.44 (1.13­5.25)
20­24   43 (2.3)   1,866 (97.7) 1.31 (0.94­1.81)
25­29 160 (1.8)   8,794 (98.2) 1.03 (0.84­1.26)
30­34 236 (1.7) 13,369 (98.3) Ref.
35­39 158 (2.2)   7,015 (97.8) 1.28 (1.04­1.56)
≥ 40   34 (2.3)   1,453 (97.7) 1.37 (0.92­1.91)
Data missing     0 (– )      318 (–) –
Total 638 32,978 –
Parity, no. of previous births 0.0009
0 306  (1.7) 17,885 (98.3) Ref.
1 213 (2.0) 10,600 (98.0) 1.17 (0.98­1.40)
2   82 (2.6)   3,068 (97.4) 1.56 (1.22­2.00)
≥ 3   37 (2.5)   1,425 (97.5) 1.52 (1.07­2.14)
Data missing     0 (–)           0 (–) –
Total 638 32,978 – 
Outcomes 
Gestational age at birth, 
weeks
< 0.0001
< 28   28 (4.5)      763 (2.2) –
28­31   30 (4.8)      707 (2.1) –
32­36   86 (13.7)   2,890 (8.4) –
37­41 412 (65.5) 28,482 (82.5) –
≥ 42   73 (11.6)   1,704 (4.9) –
Data missing     9 (–)           7 (–) –
Total 638 34,553b  –
Birth weight, g < 0.0001
≤ 999   25 (4.0)      779 (2.2) –
1,000­1,999   59 (9.4)   1,257 (3.7) –
2,000­2,999 158 (25.2)   6,205 (18.1) –
3,000­3,999 344 (54.7) 21,525 (62.4) –
4,000­4,499   33 (5.3)   3,934 (11.4) –
≥ 4,500     9 (1.4)      773 (2.2) –
Data missing   10 (–)        56 (–) –
Total 613 34,529b –
Mode of delivery  < 0.0001
Vaginal (non­instrumental) 234 (36.7) 21,543 (65.3) –
Vaginal (instrumental)   77 (12.1)   2,802 (8.5) –
Elective caesarean section 141 (22.1)   4,131 (12.5) –
Acute caesarean section 186 (29.1)   4,502 (13.7) –
Data missing     0 (–)           0 (–) –
Total 638 32,978 –
CI = confidence interval; GBS = group B streptococci; OR = odds ratio. 
a) Pearson χ2­test. 
b) Due to multiple pregnancies, the number of babies exceeds the number of births (39 GBS multiple 
pregnancies).
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GBS bacteriuria in pregnant women is a marker for 
heavy colonisation and an increased risk of EOGBS [10]. 
This emphasises the importance of detecting GBS in 
pregnancy in order to be able to devise a relevant IAP 
strategy. Whether or not to screen all pregnant women 
remains a controversial issue, but since the Centre for 
Disease Control (CDC) and the American College of 
Obstetricians and Gynecologists (ACOG) introduced a na­
tional screening programme in 1996, the prevalence of 
EOGBS has declined substantially in the US [10]. By 2008, 
the incidence diminished from 1.5­1.7 cases per 1,000 
live births to 0.34, i.e. a decrease of more than 80% [4]. 
Routine screening has now been introduced in Australia, 
Spain, Italy, Belgium and Germany [19]. The efficacy of a 
vaginal screening regime significantly reduces the risk of 
neonatal EOGBS (RR 0.5, 95% CI (0.4­0.6)) [5]. 
A total of 19% of the babies with EOGBS in this study 
were born prematurely (28­36 gestational week) and 
49% born very prematurely (< 28 gestational week). The 
fact that the mortality is higher among preterm infants 
with EOGBS, with case­fatality rates of approximately 
20% and reaching 30% among those ≤ 33 gestation 
weeks compared with 2­3% among full­term infants un­
derlines the severity of the increase in GBS colonisation 
among pregnant women [1]. There were no deaths in our 
neonatal GBS cohort, which could be owed to the highly 
specialised and advanced neonatal care on the RH.
A recent Cochrane review concluded that most 
studies conducted on GBS colonisation are biased due to 
methodological weaknesses and that there is a lack of 
evidence from well­designed and well­conducted trials 
to recommend IAP to reduce neonatal EOGBS and that 
the effectiveness of IAP should be studied in RCTs [20]. 
CONCLUSION
GBS colonisation among pregnant women remains the 
leading cause of serious neonatal infections with EOGBS 
and attention to this condition is warranted. Changing 
the antenatal care recommendations in Denmark from 
the existing risk­factor­based IAP to a national screening 
procedure and hence a substantial increase in the use of 
IAP could be a cost­full and time­consuming process, 
and neither this study nor the available literature in the 
field provide sufficient grounds for changing the present 
practices, and further randomised studies are therefore 
needed.
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